{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T23:01:26Z","timestamp":1780959686291,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Edge Therapeutics, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2019,2,15]]},"DOI":"10.1007\/s12028-018-0575-z","type":"journal-article","created":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T16:26:36Z","timestamp":1531758396000},"page":"88-97","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Clinical Trial Protocol: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage [NEWTON-2 (Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After SubarachNoid Hemorrhage)]"],"prefix":"10.1007","volume":"30","clinical-trial-number":[{"clinical-trial-number":"nct02790632","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Daniel","family":"H\u00e4nggi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Etminan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan A.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Francois","family":"Aldrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N.","family":"Diringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Schmutzhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert J.","family":"Faleck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin R.","family":"Saville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Loch","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the NEWTON Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,16]]},"reference":[{"key":"575_CR1","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"key":"575_CR2","first-page":"CD000277","volume":"3","author":"SM Dorhout Mees","year":"2007","unstructured":"Dorhout Mees SM, Rinkel GJ, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007;3:CD000277.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"575_CR3","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S1474-4422(09)70126-7","volume":"8","author":"DJ Nieuwkamp","year":"2009","unstructured":"Nieuwkamp DJ, Setz LE, Algra A, et al. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol. 2009;8(7):635\u201342.","journal-title":"Lancet Neurol"},{"issue":"1","key":"575_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12028-015-0230-x","volume":"25","author":"N Sandow","year":"2016","unstructured":"Sandow N, Diesing D, Sarrafzadeh A, Vajkoczy P, Wolf S. Nimodipine dose reductions in the treatment of patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2016;25(1):29\u201339.","journal-title":"Neurocrit Care"},{"issue":"5","key":"575_CR5","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00701-015-2369-9","volume":"157","author":"T Abboud","year":"2015","unstructured":"Abboud T, Andresen H, Koeppen J, et al. Serum levels of nimodipine in enteral and parenteral administration in patients with aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien). 2015;157(5):763\u20137.","journal-title":"Acta Neurochir (Wien)"},{"issue":"2","key":"575_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s13311-016-0424-8","volume":"13","author":"D Hanggi","year":"2016","unstructured":"Hanggi D, Etminan N, Steiger HJ, et al. A site-specific, sustained-release drug delivery system for aneurysmal Subarachnoid hemorrhage. Neurotherapeutics. 2016;13(2):439\u201349.","journal-title":"Neurotherapeutics"},{"issue":"11","key":"575_CR7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJM198303173081103","volume":"308","author":"GS Allen","year":"1983","unstructured":"Allen GS, Ahn HS, Preziosi TJ, et al. Cerebral arterial spasm\u2013a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983;308(11):619\u201324.","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"575_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/BF02188783","volume":"137","author":"F Porchet","year":"1995","unstructured":"Porchet F, Chiolero R, de Tribolet N. Hypotensive effect of nimodipine during treatment for aneurysmal subarachnoid haemorrhage. Acta Neurochir. 1995;137(1\u20132):62\u20139.","journal-title":"Acta Neurochir"},{"issue":"4","key":"575_CR9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3171\/jns.1988.68.4.0505","volume":"68","author":"KC Petruk","year":"1988","unstructured":"Petruk KC, West M, Mohr G, et al. Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg. 1988;68(4):505\u201317.","journal-title":"J Neurosurg"},{"issue":"2","key":"575_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1179\/1743132812Y.0000000124","volume":"35","author":"AM Burrows","year":"2013","unstructured":"Burrows AM, Korumilli R, Lanzino G. How we do it: acute management of subarachnoid hemorrhage. Neurol Res. 2013;35(2):111\u20136.","journal-title":"Neurol Res"},{"issue":"9","key":"575_CR11","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1007\/s00134-009-1533-1","volume":"35","author":"RD Stevens","year":"2009","unstructured":"Stevens RD, Naval NS, Mirski MA, Citerio G, Andrews PJ. Intensive care of aneurysmal subarachnoid hemorrhage: an international survey. Intensive Care Med. 2009;35(9):1556\u201366.","journal-title":"Intensive Care Med"},{"issue":"5","key":"575_CR12","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S1474-4422(10)70087-9","volume":"9","author":"AA Rabinstein","year":"2010","unstructured":"Rabinstein AA, Lanzino G, Wijdicks EF. Multidisciplinary management and emerging therapeutic strategies in aneurysmal subarachnoid haemorrhage. Lancet Neurol. 2010;9(5):504\u201319.","journal-title":"Lancet Neurol"},{"issue":"2","key":"575_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12028-011-9605-9","volume":"15","author":"MN Diringer","year":"2011","unstructured":"Diringer MN, Bleck TP, Hemphill CJ III, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society\u2019s Multidisciplinary Consensus Conference. Neurocrit Care. 2011;15(2):211\u201340.","journal-title":"Neurocrit Care"},{"issue":"2","key":"575_CR14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1161\/01.STR.0000254601.74596.0f","volume":"38","author":"M Barth","year":"2007","unstructured":"Barth M, Capelle HH, Weidauer S, et al. Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurysmal subarachnoid hemorrhage: a prospective, randomized, double-blind phase IIa study. Stroke. 2007;38(2):330\u20136.","journal-title":"Stroke"},{"issue":"5","key":"575_CR15","first-page":"895","volume":"56","author":"H Kasuya","year":"2005","unstructured":"Kasuya H, Onda H, Sasahara A, Takeshita M, Hori T. Application of nicardipine prolonged-release implants: analysis of 97 consecutive patients with acute subarachnoid hemorrhage. Neurosurgery. 2005;56(5):895\u2013902.","journal-title":"Neurosurgery"},{"issue":"3","key":"575_CR16","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12028-011-9659-8","volume":"16","author":"N Lu","year":"2012","unstructured":"Lu N, Jackson D, Luke S, et al. Intraventricular nicardipine for aneurysmal subarachnoid hemorrhage related vasospasm: assessment of 90\u00a0days outcome. Neurocrit Care. 2012;16(3):368\u201375.","journal-title":"Neurocrit Care"},{"issue":"1","key":"575_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000354755","volume":"2","author":"G Dabus","year":"2013","unstructured":"Dabus G, Nogueira RG. Current options for the management of aneurysmal subarachnoid hemorrhage-induced cerebral vasospasm: a comprehensive review of the literature. Interv Neurol. 2013;2(1):30\u201351.","journal-title":"Interv Neurol"},{"issue":"3","key":"575_CR18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/neurintsurg-2011-010248","volume":"4","author":"T Abruzzo","year":"2012","unstructured":"Abruzzo T, Moran C, Blackham KA, et al. Invasive interventional management of post-hemorrhagic cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurointerv Surg. 2012;4(3):169\u201377.","journal-title":"J Neurointerv Surg"},{"issue":"8","key":"575_CR19","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.clineuro.2008.05.001","volume":"110","author":"D Hanggi","year":"2008","unstructured":"Hanggi D, Beseoglu K, Turowski B, Steiger HJ. Feasibility and safety of intrathecal nimodipine on posthaemorrhagic cerebral vasospasm refractory to medical and endovascular therapy. Clin Neurol Neurosurg. 2008;110(8):784\u201390.","journal-title":"Clin Neurol Neurosurg"},{"issue":"3","key":"575_CR20","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s12028-011-9537-4","volume":"15","author":"N Rosenberg","year":"2011","unstructured":"Rosenberg N, Lazzaro MA, Lopes DK, Prabhakaran S. High-dose intra-arterial nicardipine results in hypotension following vasospasm treatment in subarachnoid hemorrhage. Neurocrit Care. 2011;15(3):400\u20134.","journal-title":"Neurocrit Care"},{"issue":"1","key":"575_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nrneurol.2013.246","volume":"10","author":"RL Macdonald","year":"2014","unstructured":"Macdonald RL. Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol. 2014;10(1):44\u201358.","journal-title":"Nat Rev Neurol"},{"issue":"Pt 7","key":"575_CR22","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1093\/brain\/awp102","volume":"132","author":"JP Dreier","year":"2009","unstructured":"Dreier JP, Major S, Manning A, et al. Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. Brain. 2009;132(Pt 7):1866\u201381.","journal-title":"Brain"},{"issue":"1","key":"575_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.expneurol.2011.10.029","volume":"233","author":"JM Pisapia","year":"2012","unstructured":"Pisapia JM, Xu X, Kelly J, et al. Microthrombosis after experimental subarachnoid hemorrhage: time course and effect of red blood cell-bound thrombin-activated pro-urokinase and clazosentan. Exp Neurol. 2012;233(1):357\u201363.","journal-title":"Exp Neurol"},{"issue":"12","key":"575_CR24","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1161\/STROKEAHA.112.669788","volume":"43","author":"KP Budohoski","year":"2012","unstructured":"Budohoski KP, Czosnyka M, Smielewski P, et al. Impairment of cerebral autoregulation predicts delayed cerebral ischemia after subarachnoid hemorrhage: a prospective observational study. Stroke. 2012;43(12):3230\u20137.","journal-title":"Stroke"},{"issue":"12","key":"575_CR25","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/jcbfm.2013.173","volume":"33","author":"L Ostergaard","year":"2013","unstructured":"Ostergaard L, Aamand R, Karabegovic S, et al. The role of the microcirculation in delayed cerebral ischemia and chronic degenerative changes after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2013;33(12):1825\u201337.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"10069","key":"575_CR26","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0140-6736(16)30668-7","volume":"389","author":"RL Macdonald","year":"2017","unstructured":"Macdonald RL, Schweizer TA. Spontaneous subarachnoid haemorrhage. Lancet. 2017;389(10069):655\u201366.","journal-title":"Lancet"},{"issue":"1","key":"575_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.pneurobio.2012.02.003","volume":"97","author":"FA Sehba","year":"2012","unstructured":"Sehba FA, Hou J, Pluta RM, Zhang JH. The importance of early brain injury after subarachnoid hemorrhage. Prog Neurobiol. 2012;97(1):14\u201337.","journal-title":"Prog Neurobiol"},{"key":"575_CR28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/978-3-319-04981-6_47","volume":"120","author":"N Etminan","year":"2015","unstructured":"Etminan N, Macdonald RL, Davis C, et al. Intrathecal application of the nimodipine slow-release microparticle system eg-1962 for prevention of delayed cerebral ischemia and improvement of outcome after aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl. 2015;120:281\u20136.","journal-title":"Acta Neurochir Suppl"},{"issue":"2","key":"575_CR29","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s12028-015-0112-2","volume":"23","author":"D Hanggi","year":"2015","unstructured":"Hanggi D, Etminan N, Macdonald RL, et al. NEWTON: Nimodipine microparticles to Enhance recovery While reducing TOxicity after subarachNoid hemorrhage. Neurocrit Care. 2015;23(2):274\u201384.","journal-title":"Neurocrit Care"},{"issue":"1","key":"575_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/STROKEAHA.116.014250","volume":"48","author":"D Hanggi","year":"2017","unstructured":"Hanggi D, Etminan N, Aldrich F, et al. Randomized, open-label, phase 1\/2a study to determine the maximum tolerated dose of intraventricular sustained release nimodipine for subarachnoid hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage]). Stroke. 2017;48(1):145\u201351.","journal-title":"Stroke"},{"issue":"4","key":"575_CR31","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"575_CR32","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nrneurol.2016.89","volume":"12","author":"T McMillan","year":"2016","unstructured":"McMillan T, Wilson L, Ponsford J, et al. The glasgow outcome scale\u201440\u00a0years of application and refinement. Nat Rev Neurol. 2016;12(8):477\u201385.","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"575_CR33","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1161\/STROKEAHA.110.589275","volume":"41","author":"MD Vergouwen","year":"2010","unstructured":"Vergouwen MD, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41(10):2391\u20135.","journal-title":"Stroke"},{"issue":"5","key":"575_CR34","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/01.STR.19.5.604","volume":"19","author":"JC van Swieten","year":"1988","unstructured":"van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn G. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604\u20137.","journal-title":"Stroke"},{"issue":"8","key":"575_CR35","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/S1474-4422(14)70120-6","volume":"13","author":"G Teasdale","year":"2014","unstructured":"Teasdale G, Maas A, Lecky F, et al. The glasgow coma scale at 40\u00a0years: standing the test of time. Lancet Neurol. 2014;13(8):844\u201354.","journal-title":"Lancet Neurol"},{"issue":"6","key":"575_CR36","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1161\/STR.0b013e3182587839","volume":"43","author":"ES Connolly Jr","year":"2012","unstructured":"Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association\/american Stroke Association. Stroke. 2012;43(6):1711\u201337.","journal-title":"Stroke"},{"issue":"3","key":"575_CR37","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s12028-016-0352-9","volume":"26","author":"DY Chung","year":"2017","unstructured":"Chung DY, Leslie-Mazwi TM, Patel AB, Rordorf GA. Management of external ventricular drains after subarachnoid hemorrhage: a multi-institutional survey. Neurocrit Care. 2017;26(3):356\u201361.","journal-title":"Neurocrit Care"},{"issue":"6","key":"575_CR38","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1161\/STROKEAHA.110.601211","volume":"42","author":"LA Degen","year":"2011","unstructured":"Degen LA, Dorhout Mees SM, Algra A, Rinkel GJ. Interobserver variability of grading scales for aneurysmal subarachnoid hemorrhage. Stroke. 2011;42(6):1546\u20139.","journal-title":"Stroke"},{"key":"575_CR39","first-page":"985","volume":"68","author":"CG Drake","year":"1988","unstructured":"Drake CG, Hunt WE, Sano K, et al. Report of World Federation of Neurological Surgeons committee on a universal subarachnoid hemorrhage grading scale. J Neurosurg. 1988;68:985\u20136.","journal-title":"J Neurosurg"},{"issue":"1","key":"575_CR40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1227\/01.NEU.0000218821.34014.1B","volume":"59","author":"JA Frontera","year":"2006","unstructured":"Frontera JA, Claassen J, Schmidt JM, et al. Prediction of symptomatic vasospasm after subarachnoid hemorrhage: the modified fisher scale. Neurosurgery. 2006;59(1):21\u20137.","journal-title":"Neurosurgery"},{"issue":"8","key":"575_CR41","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1089\/neu.1998.15.573","volume":"15","author":"JT Wilson","year":"1998","unstructured":"Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the glasgow outcome scale and the extended glasgow outcome scale: guidelines for their use. J Neurotrauma. 1998;15(8):573\u201385.","journal-title":"J Neurotrauma"},{"issue":"10","key":"575_CR42","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1161\/01.STR.0000089922.94684.13","volume":"34","author":"MJ Wilby","year":"2003","unstructured":"Wilby MJ, Sharp M, Whitfield PC, et al. Cost-effective outcome for treating poor-grade subarachnoid hemorrhage. Stroke. 2003;34(10):2508\u201311.","journal-title":"Stroke"},{"issue":"9307","key":"575_CR43","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S0140-6736(02)07816-9","volume":"359","author":"KF Schulz","year":"2002","unstructured":"Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what. Lancet. 2002;359(9307):696\u2013700.","journal-title":"Lancet"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-018-0575-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-018-0575-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-018-0575-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T19:52:30Z","timestamp":1693770750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-018-0575-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,16]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2,15]]}},"alternative-id":["575"],"URL":"https:\/\/doi.org\/10.1007\/s12028-018-0575-z","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,16]]},"assertion":[{"value":"16 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"RL. Macdonald receives grant support from the Brain Aneurysm Foundation and the Canadian Institutes for Health Research and is Chief Scientific Officer of Edge Therapeutics, Inc. D. H\u00e4nggi, N. Etminan, F. Aldrich, S.A. Mayer, M.N. Diringer, and E. Schmutzhard receive consulting fees from Edge Therapeutics, Inc. for serving on the steering committee for this study and for advising Edge Therapeutics, Inc. H.J. Faleck is an employee of Edge Therapeutics, Inc. D. Ng is an employee of ResearchPoint Global. B.R. Saville is an employee of Berry Consultants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}